{"id":"https://openalex.org/W4361946504","doi":"https://doi.org/10.1158/1078-0432.c.6526625","title":"Data from Phase I Study of the Anti-CD22 Antibody\u2013Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","display_name":"Data from Phase I Study of the Anti-CD22 Antibody\u2013Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361946504","doi":"https://doi.org/10.1158/1078-0432.c.6526625"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6526625","doi":"https://doi.org/10.1158/1078-0432.c.6526625","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6526625","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.c.6526625","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060314041","display_name":"Ranjana H. Advani","orcid":"https://orcid.org/0000-0002-3219-2292","observed_orcids":["https://orcid.org/0000-0002-3219-2292"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ranjana H. Advani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103559281","display_name":"Daniel J. Lebovic","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Lebovic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101500414","display_name":"Andy Chen","orcid":"https://orcid.org/0000-0001-5204-9445","observed_orcids":["https://orcid.org/0000-0001-5204-9445"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andy Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045191576","display_name":"Mark W. Brunvand","orcid":"https://orcid.org/0000-0003-1229-2699","observed_orcids":["https://orcid.org/0000-0003-1229-2699"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Brunvand","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089882481","display_name":"Andre Henri Goy","orcid":"https://orcid.org/0000-0001-5125-6522","observed_orcids":["https://orcid.org/0000-0001-5125-6522"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andre Goy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Julie E. Chang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julie E. Chang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035186913","display_name":"Ephraim P. Hochberg","orcid":"https://orcid.org/0000-0001-9050-7208","observed_orcids":["https://orcid.org/0000-0001-9050-7208"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ephraim Hochberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110457420","display_name":"Sreeni Yalamanchili","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sreeni Yalamanchili","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Robert Kahn","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Kahn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Dan Lu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dan Lu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082723850","display_name":"Priya Agarwal","orcid":"https://orcid.org/0000-0002-0779-1509","observed_orcids":["https://orcid.org/0000-0002-0779-1509","https://orcid.org/0000-0003-4252-8172"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Priya Agarwal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086858204","display_name":"Randall C. Dere","orcid":"https://orcid.org/0000-0003-4120-7828","observed_orcids":["https://orcid.org/0000-0003-4120-7828"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Randall C. Dere","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110286655","display_name":"Hsin\u2010Ju Hsieh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hsin-Ju Hsieh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009979630","display_name":"Surai Jones","orcid":"https://orcid.org/0009-0001-5168-8904","observed_orcids":["https://orcid.org/0009-0001-5168-8904"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Surai Jones","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108427126","display_name":"Yu\u2010Waye Chu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yu-Waye Chu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5082606841","display_name":"Bruce D. Cheson","orcid":"https://orcid.org/0000-0001-9255-7655","observed_orcids":["https://orcid.org/0000-0001-9255-7655","https://orcid.org/0000-0002-6246-4308"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce D. Cheson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.01489999983459711,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8629999756813049},{"id":"https://openalex.org/keywords/anti-cd22-antibody","display_name":"anti-CD22 antibody","score":0.8489999771118164},{"id":"https://openalex.org/keywords/monomethyl-auristatin-e","display_name":"monomethyl auristatin E","score":0.9559999704360962},{"id":"https://openalex.org/keywords/rituximab-combination","display_name":"rituximab combination","score":0.796999990940094},{"id":"https://openalex.org/keywords/relapsed-refractory-non-hodgkin-lymphoma","display_name":"relapsed/refractory non-Hodgkin lymphoma","score":0.9399999976158142},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9850000143051147},{"id":"https://openalex.org/keywords/indolent-non-hodgkin-lymphoma","display_name":"indolent non-Hodgkin lymphoma","score":0.9940000176429749},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.9319999814033508},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.902999997138977},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9900000095367432},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.9869999885559082},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9070000052452087},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6230000257492065},{"id":"https://openalex.org/keywords/protease-cleavable-linker","display_name":"protease-cleavable linker","score":0.8309999704360962}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8734609484672546},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.7198858261108398},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.707302451133728},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6746113300323486},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6599102020263672},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.653282880783081},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5532544851303101},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.49608930945396423},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.484966516494751},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.47331249713897705},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3578212559223175},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32267481088638306},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2647964358329773},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.21350765228271484},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1780271828174591},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.14598190784454346},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.c.6526625","doi":"https://doi.org/10.1158/1078-0432.c.6526625","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6526625","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.c.6526625.v1","doi":"https://doi.org/10.1158/1078-0432.c.6526625.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6526625.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6526625","doi":"https://doi.org/10.1158/1078-0432.c.6526625","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6526625","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1977824829","https://openalex.org/W2011118089","https://openalex.org/W2060466778","https://openalex.org/W2065528643","https://openalex.org/W2090057677","https://openalex.org/W2101893838","https://openalex.org/W2120755425","https://openalex.org/W2126855868","https://openalex.org/W2127018518","https://openalex.org/W2127749132","https://openalex.org/W2133201432","https://openalex.org/W2134861285","https://openalex.org/W2142099365","https://openalex.org/W2142195688","https://openalex.org/W2143154854","https://openalex.org/W2150587745","https://openalex.org/W2155256323","https://openalex.org/W2156506990","https://openalex.org/W2158346246","https://openalex.org/W2161054245","https://openalex.org/W2164006259","https://openalex.org/W2531182358"],"related_works":["https://openalex.org/W2508961955","https://openalex.org/W2127018518","https://openalex.org/W2404824632","https://openalex.org/W2934686121","https://openalex.org/W2597981368","https://openalex.org/W4232044877","https://openalex.org/W1024621933","https://openalex.org/W3206176119","https://openalex.org/W2765568148","https://openalex.org/W4362491081"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"Pinatuzumab":[2],"vedotin":[3,68,220,238],"is":[4],"an":[5,19],"antibody\u2013drug":[6],"conjugate":[7],"with":[8,47,79,196,218,241,250],"the":[9,75,149,153,200],"potent":[10],"antimicrotubule":[11],"agent":[12],"monomethyl":[13],"auristatin":[14],"E":[15],"(MMAE)":[16],"conjugated":[17],"to":[18],"anti-CD22":[20],"antibody":[21],"via":[22],"a":[23],"protease-cleavable":[24],"linker.":[25],"This":[26],"phase":[27,33],"I":[28],"study":[29],"determined":[30],"its":[31,39],"recommended":[32],"II":[34],"dose":[35],"(RP2D)":[36,221],"and":[37,42,46,55,90,124,209,222,240],"evaluated":[38,82],"safety,":[40,177],"tolerability,":[41,178],"antitumor":[43],"activity":[44,73,253],"alone":[45,77,239],"rituximab":[48,80,223,242],"in":[49,83,119,130,169,206,254],"relapsed/refractory":[50],"(r/r)":[51],"non-Hodgkin":[52],"lymphoma":[53,88],"(NHL)":[54],"chronic":[56],"lymphocytic":[57],"leukemia":[58],"(CLL).":[59],"Experimental":[60],"Design:":[61],"Patients":[62],"received":[63,99],"escalating":[64],"doses":[65],"of":[66,113,121,132,181,214,236],"pinatuzumab":[67,101,182,219,237],"every":[69],"21":[70],"days.":[71],"Clinical":[72],"at":[74,136,145],"RP2D":[76,104,235],"or":[78,179],"was":[81,105,152,187,243,247],"r/r":[84,91,255],"diffuse":[85],"large":[86],"B-cell":[87],"(DLBCL)":[89],"indolent":[92],"NHL":[93],"(iNHL)":[94],"patients.":[95],"Results:":[96],"Seventy-five":[97],"patients":[98,123,134,216,228],"single-agent":[100],"vedotin.":[102,183],"The":[103,234],"2.4":[106,146,244],"mg/kg,":[107,245],"based":[108],"on":[109],"dose-limiting":[110],"toxicities":[111],"(DLT)":[112],"grade":[114,125,156,162],"4":[115,126],"neutropenia":[116,127,151],">7":[117],"days":[118,129],"1":[120],"3":[122,133],"<7":[128],"2":[131,213],"treated":[135,217],"3.2":[137],"mg/kg":[138],"(maximum":[139],"assessed":[140],"dose).":[141],"No":[142],"DLTs":[143],"occurred":[144],"mg/kg.":[147],"At":[148,199],"RP2D,":[150,201],"most":[154,166],"common":[155],"\u22653":[157],"adverse":[158,164],"event.":[159],"Peripheral":[160],"neuropathy\u2013related":[161],"\u22652":[163],"events":[165],"frequently":[167],"resulted":[168],"treatment":[170],"discontinuation.":[171],"Rituximab":[172],"cotreatment":[173],"did":[174],"not":[175],"impact":[176],"pharmacokinetics":[180],"Unconjugated":[184],"MMAE":[185,192],"exposure":[186],"much":[188],"lower":[189],"than":[190],"antibody-conjugated":[191],"exposure,":[193],"without":[194],"accumulation":[195],"repeat":[197],"dosing.":[198],"objective":[202,231],"responses":[203],"were":[204],"observed":[205],"DLBCL":[207],"(9/25)":[208],"iNHL":[210],"(7/14)":[211],"patients;":[212],"8":[215],"had":[224],"complete":[225],"responses.":[226,232],"CLL":[227],"showed":[229],"no":[230],"Conclusions:":[233],"which":[246],"well":[248],"tolerated,":[249],"encouraging":[251],"clinical":[252],"NHL.":[256],"Clin":[257],"Cancer":[258],"Res;":[259],"23(5);":[260],"1167\u201376.":[261],"\u00a92016":[262],"AACR.":[263]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}